181 related articles for article (PubMed ID: 12353631)
1. Inhibitory properties of antitumor prostaglandins against topoisomerases.
Suzuki K; Uyeda M
Biosci Biotechnol Biochem; 2002 Aug; 66(8):1706-12. PubMed ID: 12353631
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of topoisomerases by antitumor prostaglandins.
Suzuki K; Shono F; Uyeda M
Biosci Biotechnol Biochem; 1998 Oct; 62(10):2073-5. PubMed ID: 9836448
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II.
Suzuki K; Yahara S; Hashimoto F; Uyeda M
Biol Pharm Bull; 2001 Sep; 24(9):1088-90. PubMed ID: 11558576
[TBL] [Abstract][Full Text] [Related]
4. 2070-DTI, a topoisomerase inhibitor produced by Streptomyces sp. strain No. 2070.
Suzuki K; Doi S; Yahara S; Uyeda M
J Enzyme Inhib Med Chem; 2003 Dec; 18(6):497-503. PubMed ID: 15008514
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
[TBL] [Abstract][Full Text] [Related]
6. The role of c-Myc and heat shock protein 70 in human hepatocarcinoma Hep3B cells during apoptosis induced by prostaglandin A2/Delta12-prostaglandin J2.
Ahn SG; Jeong SY; Rhim H; Kim IK
Biochim Biophys Acta; 1998 Nov; 1448(1):115-25. PubMed ID: 9824682
[TBL] [Abstract][Full Text] [Related]
7. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
9. Delta12-Prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition.
Li Z; Melandri F; Berdo I; Jansen M; Hunter L; Wright S; Valbrun D; Figueiredo-Pereira ME
Biochem Biophys Res Commun; 2004 Jul; 319(4):1171-80. PubMed ID: 15194490
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities.
Umemura K; Mizushima T; Katayama H; Kiryu Y; Yamori T; Andoh T
Mol Pharmacol; 2002 Oct; 62(4):873-80. PubMed ID: 12237334
[TBL] [Abstract][Full Text] [Related]
11. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of growth in oral squamous carcinoma cells by cyclopentenone prostaglandins: comparison with chemotherapeutic agents.
ElAttar TM; Virji AS
Prostaglandins Leukot Essent Fatty Acids; 1997 Jun; 56(6):461-5. PubMed ID: 9223658
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
14. Interaction of strong DNA-intercalating bioreductive compounds with topoisomerases I and II.
Rosenzweig HS; Papadopoulou MV; Bloomer WD
Oncol Res; 2005; 15(4):219-31. PubMed ID: 17822282
[TBL] [Abstract][Full Text] [Related]
15. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
[TBL] [Abstract][Full Text] [Related]
16. Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Peleg R; Romzova M; Kogan-Zviagin I; Apte RN; Priel E
BMC Cancer; 2014 Dec; 14():910. PubMed ID: 25472619
[TBL] [Abstract][Full Text] [Related]
17. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
18. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM
Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
